The performance of companies tied to blockbuster drugs like Viagra presents a nuanced investment picture. While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the patent expiration in key regions has introduced considerable uncertainty . Investors are now assessing the consequences of generi